CNS immunological modulation of neural graft rejection and survival.
Neural transplantation therapy as a possible alternative treatment for neurological movement disorders, such as in Parkinson's disease (PD), has accentuated research interest on the immune status of the central nervous system (CNS). Most animal studies concerned with neural transplantation for the treatment of PD have utilized dopamine (DA) neurons from tissues of the embryonic ventral mesencephalon. Rat embryonic DA neurons, grafted either as solid blocks or dissociated into a cell suspension and stereotaxically injected intraparenchymally into a rat lesion model of PD, have been shown to survive and form connections with the host brain, and ameliorate the behavioral deficits of PD. Similarly, studies on nonhuman primate models of PD provide considerable support for neural transplantation of DA neurons as an experimental clinical procedure for the treatment of PD. To this end, experimental clinical trials have been centered upon transplantation of the embryonic ventral mesencephalic cells for PD patients. Although not conclusive, the findings from clinical studies have provided some evidence that most patients with marked increases in fluorodopa uptake (indicating graft survival) have been immunosuppressed. Furthermore, immune reactions have been observed in rats xenografted with human embryonic tissue. Of note, embryonic ventral mesencephalic tissues compared to adult tissues produce better morphological and long-lasting behavioral amelioration of the neurobehavioral deficits of PD, thus advocating the use of grafts from young donors (embryo) to circumvent the CNS immune rejection. The possible graft rejection due to CNS immune reactions, coupled with the social and ethical problems surrounding the use of embryonic neural tissue, and the logistical problems concerning tissue availability have prompted the development of alternative sources of DA-secreting cells. To circumvent these obstacles, several methods have been suggested including the use of immunosuppressants such as Cyclosporine-A, transplantation of autografts, polymer-encapsulated DA-secreting cells, co-culturing and co-transplantation of DA-secreting cells with microcarrier beads, with Sertoli cells, or with fragments of a monoclonal antibody that can mask the MHC class I antigens, and genetically modifying cells that can withstand CNS immune reactions. Some of these techniques allow transplantation of allograft (same species transplantation), or even xenograft (cross species transplantation) without immunosuppression of the recipient. We discuss recent CNS immunosuppression techniques that pose some promise for enhanced survival of neural grafts. When possible, advantages and disadvantages of each method are presented. Hopefully, such critical analysis of different immunosuppression techniques will produce innovated ideas that will lead to a better understanding of CNS immune response and its modulatory function on graft rejection and survival.
Borlongan
C V
CV
Department of Surgery, University of South Florida College of Medicine, Tampa 33612, USA.
Stahl
C E
CE
Cameron
D F
DF
Saporta
S
S
Freeman
T B
TB
Cahill
D W
DW
Sanberg
P R
PR
D000313:Adrenal Medulla / Q000637:transplantation; D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D001921:Brain / Q000276:immunology*; D016380:Brain Tissue Transplantation / Q000276:immunology*; D017690:Cell Transplantation; D016572:Cyclosporine / Q000627:therapeutic use; D004298:Dopamine / Q000378:metabolism; D004339:Drug Compounding; D016332:Fetal Tissue Transplantation / Q000276:immunology*; D015316:Genetic Therapy; D005822:Genetic Vectors; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008636:Mesencephalon / Q000276:immunology / Q000637:transplantation*; D051379:Mice; D010300:Parkinson Disease / Q000601:surgery; D011323:Primates; D051381:Rats; D012708:Sertoli Cells / Q000637:transplantation; D014183:Transplantation, Heterologous; D016042:Transplantation, Heterotopic; D014446:Tyrosine 3-Monooxygenase / Q000172:deficiency / Q000235:genetics
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine